Current Hematologic Malignancy Reports

, Volume 6, Issue 3, pp 164–171

The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma

  • Teresa V. Halbsguth
  • Boris Böll
  • Peter Borchmann
  • Volker Diehl
Article

DOI: 10.1007/s11899-011-0089-7

Cite this article as:
Halbsguth, T.V., Böll, B., Borchmann, P. et al. Curr Hematol Malig Rep (2011) 6: 164. doi:10.1007/s11899-011-0089-7

Abstract

In recent decades, the prognosis of Hodgkin lymphoma has been substantially improved, but these successes have been restricted to younger patients and could not be translated into a major benefit for older patients, especially those with advanced-stage disease. Major problems in treating older patients include a different biology, frailty, comorbidities, and poorer tolerance of therapy. Additionally, these patients are often excluded from randomized trials, so an evidence-based standard of care is lacking. Importantly, the proportion of older patients with HL will increase over the next 50 years. Currently, ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine) is considered to be the gold standard, even though it has some toxicity in older patients and prospective data are not available. Thus, further studies are required, including the assessment of comorbidities and the incorporation of new drugs such as immunomodulatory agents, antibody-drug conjugates, mTOR inhibitors, or histone deacetylase (HDAC) inhibitors.

Keywords

Hodgkin lymphomaHodgkin diseaseOlderElderlyManagementTreatmentComorbidityToxicity, therapy-associated deathTreatment-related morbidityABVD

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Teresa V. Halbsguth
    • 1
  • Boris Böll
    • 1
  • Peter Borchmann
    • 1
  • Volker Diehl
    • 1
  1. 1.First Department of Internal Medicine, German Hodgkin Study Group (GHSG)University of CologneCologneGermany